Dybal E J, Haas G P, Maughan R L, Sud S, Pontes J E, Hillman G G
Department of Veterans Affairs, VA Medical Center, Allen Park, Michigan.
J Urol. 1992 Oct;148(4):1331-7. doi: 10.1016/s0022-5347(17)36903-3.
The treatment of metastatic renal cell carcinoma with immunotherapy has resulted in objective anti-tumor responses in 15-30% of patients. To enhance the therapeutic effects of immunotherapy, it is becoming evident that this approach should be combined with other treatment modalities. In this study, a spontaneously metastasizing murine renal adenocarcinoma (Renca), transplanted under the renal capsule, was treated with either radiation therapy, immunotherapy or a combination of both. In order to distinguish between the local and systemic effects of radiation therapy, total body irradiation was compared to irradiation of the tumor-bearing kidney only, or irradiation of the whole mouse with the tumor-bearing kidney shielded. Immunotherapy was administered with interleukin-2 (IL-2) alone or with IL-2 and lymphokine activated killer (LAK) cells. Combined radiation and immunotherapy induced a better anti-tumor response than either modality alone. The best response was obtained by local tumor irradiation and IL-2 therapy and resulted in a significant reduction in primary tumor size, elimination of lung metastases and a significant increase in survival.
免疫疗法治疗转移性肾细胞癌已使15%至30%的患者出现客观抗肿瘤反应。为提高免疫疗法的治疗效果,越来越明显的是,这种方法应与其他治疗方式联合使用。在本研究中,将自发转移的小鼠肾腺癌(Renca)移植到肾被膜下,分别采用放射治疗、免疫疗法或两者联合进行治疗。为区分放射治疗的局部和全身效应,将全身照射与仅照射荷瘤肾脏或对荷瘤肾脏进行屏蔽的全小鼠照射进行了比较。免疫疗法单独使用白细胞介素-2(IL-2)或联合IL-2和淋巴因子激活的杀伤细胞(LAK)进行给药。放射治疗与免疫疗法联合使用比单独使用任何一种方式诱导出更好的抗肿瘤反应。通过局部肿瘤照射和IL-2治疗获得了最佳反应,导致原发肿瘤大小显著减小、肺转移灶消除且生存率显著提高。